Orlando, FL -- (SBWIRE) -- 09/25/2013 -- Hot Stock Profits provides investors and traders with valuable trading tools and content as well as micro-cap stock alerts via eMail and text messages. To Join Our Text Message Alerts Service Just Text The Word Stocks To 555888 From Your Cell Phone. Our Focus Today Is On PepsiCo, Inc.(NYSE:PEP), Eli Lilly & Co. (NYSE:LLY).
PepsiCo, Inc.(NYSE:PEP) shares dropped 0.59% to $80.54. The company announced that its third quarter 2013 earnings conference call for financial analysts and investors will be webcast on Wednesday, October 16, at 8 a.m. Eastern Daylight Time (EDT).
Additionally, the company on Sept. 23 announced the appointment of Sanjeev Chadha to the position of Chief Executive Officer, Asia, Middle East and Africa (AMEA), effective immediately. In this role, Chadha will report to Chairman and CEO Indra K. Nooyi and oversee all aspects of PepsiCo's AMEA business. Chadha most recently served as President, PepsiCo Middle East and Africa.
Moreover, the company on Sept. 18 announced it is the exclusive food and beverage launch partner for iTunes Radio, Apple's new iAd-supported streaming radio service which went live today with iOS 7. On iTunes Radio, PepsiCo will deliver custom experiences across PepsiCo brands, as well as branded channels within iTunes Radio, reaching millions of consumers on their iPhone, iPad, iPod touch, Apple TV, Mac or PC. These innovative experiences will be a vehicle to foster discovery of new global artists and highlight connections between music and other pillars of pop culture such as sports.
Are investors worried about the recent updates with PEP? Find out with a free trend analysis HERE
Eli Lilly & Co. (NYSE:LLY) shares declined 1.15% to $52.43. Boehringer Ingelheim and Eli Lilly and Company (Lilly; NYSE: LLY) on Sept. 24 announced results from two post-hoc, pooled analyses of data from placebo-controlled clinical trials, which examined the safety of the dipeptidyl peptidase-4 (DPP-4) inhibitor linagliptin in adults with type 2 diabetes (T2D). These data were presented at the 49th Annual Meeting of the European Association for the Study of Diabetes (EASD).
Linagliptin, which is marketed as TRADJENTA® (linagliptin) tablets in the U.S., is a once-daily, 5 mg tablet used along with diet and exercise to improve glycemic control in adults with type 2 diabetes.
Additionally, LLY‘s stock had its “buy” rating reiterated by Sanford C. Bernstein in a research note issued on Sept. 25. They currently have a $61.00 price target on the stock. Sanford C. Bernstein’s price target points to a potential upside of 16.35% from the company’s current price.
Is LLY going to continue its rally or drop like a rock? Find out with a free trend analysis HERE
Join Our Mobile SMS Alerts By Texting Stocks To 555888
HotStockProfits.com continuously monitors and scans the markets for day trading and swing trading signals on NASDAQ, NYSE, AMEX, OTCBB and Pink Sheet companies for its free e-newsletter subscribers.
HotStockProfits.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit HotStockProfits.com website, for complete risks and disclosures.
Copyright © 2005-2013 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)